Results 21 to 30 of about 4,265 (97)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism

Frontiers in Endocrinology, 2018
Cinacalcet, a calcimimetic drug, is considered a safe and valid option for the treatment of hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.
Giulia Di Dalmazi, Cesidio Giuliani, Giorgio Napolitano   +2 more
doaj   +1 more source

PLEIOTROPIC EFFECTS OF PARATHYROIDECTOMY AND AGONIST CALCIUM-SENSITIVE RECEPTOR, CINACALCET

Рациональная фармакотерапия в кардиологии, 2015
Aim. To evaluate the effect of parathyroidectomy and cinacalcet on anemia, lipid profile and blood pressure (BP) in uremic hyperparathyroidism.Material and methods. Uremic patients (n=39) treated with hemodialysis and having secondary hyperparathyroidism
L. V. Egshatyan, L. Ya. Rozhinskaya, N. S. Kuznetsov, M. Sh. Shamkhalova   +3 more
doaj   +3 more sources

The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism

Renal Failure, 2019
Background: Secondary hyperparathyroidism (SHPT) is associated with high incidences of cardiovascular disease, bone fracture, and mortality. This study was conducted to demonstrate the effectiveness of cinacalcet treatment on chronic kidney disease ...
Paweena Susantitaphong, Somratai Vadcharavivad, Teerada Susomboon, Wanchana Singhan, Netsiri Dumrongpisutikul, Ketsuda Jakchairoongruang, Somchai Eiam-Ong, Kearkiat Praditpornsilpa   +7 more
doaj   +1 more source

Cinacalcet in peritoneal dialysis patients: one-center experience

Brazilian Journal of Nephrology
Introduction: Secondary hyperparathyroidism is the target of several therapeutic strategies, including the use of cinacalcet. Most studies were done only in hemodialysis patients, with few data from peritoneal dialysis patients.
Sara Querido Conde, Patrícia Branco, Henrique Sousa, Teresa Adragão, Augusta Gaspar, José Diogo Barata   +5 more
doaj   +1 more source

Hereditary Vitamin-D Dependent Rickets Type II: A Case Report

Journal of Nepal Medical Association, 2021
Hereditary vitamin D dependent rickets type II is a rare genetic disorder in children characterized by early onset of rickets and deranged biochemical parameters.
Neela Sunuwar, Swotantra Gautam, Anuradha Twayana, Saroj Adhikari Yadav, Firoz Anjum, Kriti Kandel   +5 more
doaj   +1 more source

UTILIZACIÓN Y EFECTIVIDAD DE CINACALCET EN PACIENTES CON HIPERPARATIROIDISMO SECUNDARIO SOMETIDOS A HEMODIÁLISIS

Pharmaceutical Care España, 2017
Objetivo: describir la efectividad y seguridad de cinacalcet en situaciones reales así como la identificación de factores que puedan interferir en la eficacia del tratamiento con cinacalcet.
Elena Prado Mel, Maria Gil López
doaj   +2 more sources

Therapy for persistent hypercalcemic hyperparathyroidism post-renal transplant: cinacalcet versus parathyroidectomy

Brazilian Journal of Nephrology, 2020
Background: Persistent hyperparathyroidism post-transplant is associated with increases in the incidence of cardiovascular events, fractures, and deaths. The aim of this study was to compare both therapeutic options available: parathyroidectomy (PTX) and
Gabriel Giollo Rivelli, Marcelo Lopes de Lima, Marilda Mazzali   +2 more
doaj   +2 more sources

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs

Drugs in Context, 2020
Background: Patients on dialysis often have secondary hyperparathyroidism (SHPT), a disorder associated with renal osteodystrophy, progressive vascular calcification, cardiovascular disease, and death.
Alessandro Roggeri, Ferruccio Conte, Carlotta Rossi, Mario Cozzolino, Carlo Zocchetti, Daniela Paola Roggeri   +5 more
doaj   +1 more source

Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism

BMC Nephrology, 2018
Background The calcimimetic agent cinacalcet is effective for the management of secondary hyperparathyroidism (SHPT) in dialysis patients. Changes to reimbursement of cinacalcet in Australia provided an opportunity to assess effects of medication ...
Irene Ruderman, Edward R. Smith, Nigel D. Toussaint, Tim D. Hewitson, Stephen G. Holt   +4 more
doaj   +1 more source

Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide

Case Reports in Oncology, 2012
Background: Current treatments for hypercalcemia caused by lung cell carcinomas producing parathyroid hormone-related peptide (PTH-rp) have limited efficacy, probably because of their lack of effect on PTH-rp secretion. In this case study we explored the
Anneke Bech, Koen Smolders, Darryl Telting, Hans de Boer   +3 more
doaj   +1 more source